Description:

Strattera is a medication manufactured by Lilly containing the active substance Atomoxetine. It is available in capsule form with a strength of 60mg per capsule. Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.

Indications:

Strattera is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in individuals aged 6 years and older. It is used as part of a comprehensive treatment plan that may include educational, behavioral, and psychological interventions.

How It Works:

Atomoxetine works by inhibiting the reuptake of norepinephrine, a neurotransmitter involved in the regulation of attention, behavior, and impulse control. By increasing the availability of norepinephrine in the brain, Atomoxetine helps to improve attention span, reduce hyperactivity and impulsivity, and enhance executive functioning in individuals with ADHD.

Dosage and Administration:

The dosage of Strattera varies depending on factors such as the individual’s age, weight, and response to treatment. It is usually administered orally once or twice daily, with or without food. The capsules should be swallowed whole with a glass of water and should not be opened, crushed, or chewed.

Possible Side Effects:

Common side effects of Strattera may include:

1. Gastrointestinal Effects: These may include nausea, vomiting, stomach pain, and constipation.
2. Central Nervous System Effects: These may include headache, dizziness, insomnia, and fatigue.
3. Cardiovascular Effects: These may include increased heart rate, elevated blood pressure, and palpitations.
4. Psychiatric Effects: These may include mood swings, irritability, anxiety, and depression.
5. Hepatic Effects: Atomoxetine has been associated with rare cases of liver injury, including elevated liver enzymes and hepatitis.

Warnings and Precautions:

1. Suicidal Ideation: Strattera and other ADHD medications have been associated with an increased risk of suicidal ideation, particularly in children, adolescents, and young adults. Patients should be monitored for signs of depression, suicidal thoughts, and unusual changes in behavior.
2. Cardiovascular Risk: Atomoxetine may increase heart rate and blood pressure, particularly at higher doses. Patients with pre-existing cardiovascular conditions should be monitored closely while taking Strattera.
3. Hepatic Function: Liver function tests should be performed before starting treatment with Strattera and regularly thereafter, especially in patients with a history of liver disease or abnormal liver function tests.
4. Psychiatric Effects: Atomoxetine may exacerbate psychiatric conditions such as anxiety, bipolar disorder, and psychosis. Patients with a history of psychiatric disorders should be monitored for changes in mood or behavior.
5. Drug Interactions: Atomoxetine may interact with other medications, particularly those that affect the metabolism of cytochrome P450 enzymes. Patients should inform their healthcare provider of all medications they are taking.

Strattera is a prescription medication used for the treatment of attention deficit hyperactivity disorder (ADHD). Patients should follow their healthcare provider’s instructions regarding dosage, administration, and monitoring of side effects. Any concerns or potential side effects should be discussed with a healthcare professional.